Immunotherapy targeting immune checkpoint proteins, especially PD-1/PD-L1, has become an increasingly important treatment strategy for various malignancies; it has especially changed the treatment paradigm for patients with non-small cell lung cancer (NSCLC). The gene discussed is CD274; the disease is non-small cell lung carcinoma.